EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study

Olivia Lavigne, François Poumeaud, Thibaut Reverdy, Van Tuat Huynh, Guillaume Roces, Gaulthier Poupin, Maureen Gouillou, Angélique Bobrie, Emma Donadille, Florence Dalenc, William Jacot, Julien Robert und 1 weitere

Breast Cancer Research and Treatment · 2026

DOI: 10.1007/s10549-025-07893-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Olivia Lavigne und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nîmes University Hospital, Nîmes, France. olivia.lavigne@chu-nimes.fr. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The standard first-line treatment for patients with hormone receptor-positive (HR +) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer is cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy (ET). Optimal therapy after CDK4/6 inhibitors remains to be determined. We aimed to define the appropriate second-line treatment after CDK4/6 inhibitors in a real-life population. METHODS: Patients who had received CDK4/6 inhibitors with aromatase inhibitors (AIs) for HR + /HER2- metastatic breast cancer were included from March 2017 to May 2021 at five French cancer centers.The primary objective was to describe second-line treatment after primary treatment with CDK4/6 inhibitors plus AIs. RESULTS: We included 381 patients who received CDK4/6 inhibitors combined with AIs as first-line therapy. Patients with progressive disease (N = 165) benefited from a second-line of treatment: 69 (41.8%) were treated with chemotherapy, while 90 (54.6%) received endocrine therapy (ET alone: 59, 35.8%; ET plus targeted therapy: 31, 18.8%).Patients on chemotherapy were younger compared to those receiving ET (p = 0.011). Patients experiencing earlier progression were more likely to benefit from chemotherapy than ET (p = 0.001). Patients with visceral disease at diagnosis were more often treated with chemotherapy. Second-line median PFS was 6.4 months (95% CI [5.0-12.9]) for chemotherapy and 8.4 months (95% CI [5.4-11.7]) for ET ± targeted therapy, with no significant difference (HR 1.08, 95% CI [0.73-1.59], p = 0.70). CONCLUSION: This French real-world study demonstrates limited progression-free survival benefits across all second-line strategies after CDK4/6 inhibitor progression, highlighting an urgent clinical need for more effective post-progression therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Protein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 6Retrospective StudiesReceptors, EstrogenAgedAdultReceptors, ProgesteroneAged, 80 and overAromatase InhibitorsNeoplasm MetastasisTreatment Outcome

Stichwörter der Autor:innen

CDK4/6 inhibitorsEndocrine therapyMetastatic breast cancerStrategy

Substanzen

Cyclin-Dependent Kinase 4Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 6Receptors, EstrogenProtein Kinase InhibitorsReceptors, ProgesteroneCDK4 protein, humanERBB2 protein, humanCDK6 protein, humanAromatase Inhibitors

Autor:innen und Institutionen

  • Nîmes University Hospital, Nîmes, France. olivia.lavigne@chu-nimes.fr.
  • Oncopole Claudius Régaud, Toulouse, France.
  • Department of Medical Oncology, Hospices Civils de Lyon (HCL), Lyon, France.
  • Medical Oncology Department 1, Hue Central Hospital, Hue City, Vietnam.
  • Montpellier Cancer Institute, Montpellier, France.
  • INSERM U1194, Montpellier University, Montpellier, France.

Zitieren

APA

Lavigne, O., Poumeaud, F., Reverdy, T., Huynh, V. T., Roces, G., Poupin, G., Gouillou, M., Bobrie, A., Donadille, E., Dalenc, F., Jacot, W., Robert, J., & Fiteni, F. (2026). Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-025-07893-2

Vancouver

Lavigne O, Poumeaud F, Reverdy T, Huynh VT, Roces G, Poupin G, et al. Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-025-07893-2

BibTeX
@article{Lavigne2026,
  author = {Lavigne, Olivia and Poumeaud, François and Reverdy, Thibaut and Huynh, Van Tuat and Roces, Guillaume and Poupin, Gaulthier and Gouillou, Maureen and Bobrie, Angélique and Donadille, Emma and Dalenc, Florence and Jacot, William and Robert, Julien and Fiteni, Frédéric},
  title = {Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  doi = {10.1007/s10549-025-07893-2}
}
Kostenlos starten →